Company profile
UK company 12006578, incorporated on 20 May 2019.
GyreOx | Home
Gyreox Limited is a UK company with status active founded in 2019 based in South East England.
Company number 12006578
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
GyreOx develops in vitro technology that enables macrocycle production to be achieved on multiple scales.
The Company is focussed on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes.
Secured ca £1.1 M investment
GyreOx's proprietary discovery platform creates unique Gyrocycle™ highly modified macrocyclic peptides, which combine the target-engagement power of biologics with the cell-entry ability of small molecules.
We have created a chemoenzymatic technology for macrocycle generation. The technology consists of a set of flexible engineered enzymes which can carry out modification steps on a synthetic linear substrate to generate modified macrocycles.
1 Sep 2020 to 31 Aug 2022
There are two major classes of drugs: "small molecules", and, "biologics". Both have their limitations: small molecules do not address complex disease targets; whilst biologics are not able to get inside the human cell, and also have to be injected. Members of a new drug class, called "macrocycles", combine desirable properties of both these classes, in t...
